NCCN Guidelines® Insights - Breast Cancer, Version 4.2021
The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor–positive, HER2-negative breast cancer.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Breast Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
William J. Gradishar, MD, Panel Chair, has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, MacroGenics, Inc., Roche Laboratories, Inc./Genentech, Inc., Pfizer Inc., and Seattle Genetics, Inc.
Jame Abraham, MD, Panel Member, has disclosed no relevant financial relationships.
Kimberly H. Allison, MD, Panel Member, has disclosed serving as a scientific advisor for Mammotome.
Chau Dang, MD, Panel Member, has disclosed receiving grant/research support from PUMA and Roche/Genentech.
Anthony D. Elias, MD, Panel Member, has disclosed serving as a scientific advisor for Seiyax.
Sharon H. Giordano, MD, MPH, Panel Member, has disclosed no relevant financial relationships.
Matthew P. Goetz, MD, Panel Member, has disclosed serving as a scientific advisor for Biotheranostics, Novartis Pharmaceuticals Corporation, Context Therapeutics, Eagle Pharmaceuticals, Sermonix, and Pfizer Inc.; and receiving grant/research support from Eli Lilly and Company, Sermonix, and Pfizer Inc.
Sara A. Hurvitz, MD, Panel Member, has disclosed receiving grant/research support from Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Lilly, Macrogenics, Novartis Pharmaceuticals Corporation, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, and Phoenix Molecular Designs, Ltd.; having stock in NK Max; receiving consulting fees from Eli Lilly and Company; and spouse having stock in ROMTech and Ideal Implant.
Ingrid A. Mayer, MD, Panel Member, has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., GlaxoSmithKline, Immunomedics, Inc., Novartis Pharmaceuticals Corporation, Eli Lilly and Company, MacroGenics, Inc., Puma Biotechnology, and Seattle Genetics, Inc.; honoraria from AstraZeneca Pharmaceuticals LP, Genentech, Inc., and Novartis Pharmaceuticals Corporation; and grant/research support from Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Karen Lisa Smith, MD, MPH, Panel Member, has disclosed receiving equity interest/stock options in Abbott Laboratories and AbbVie, Inc.; and grant/research support from Pfizer Inc.
Hatem Soliman, MD, Panel Member, has disclosed receiving consulting fees from Immunomedics, Eisai, Novartis Pharmaceuticals Corporation, AstraZeneca, and Seattle Genetics.
John H. Ward, MD, Panel Member, has disclosed no relevant financial relationships.
Kari B. Wisinski, MD, Panel Member, has disclosed receiving grant/research support from Pfizer, AstraZeneca, Novartis Pharmaceuticals Corporation, Context, Genentech, and Sanofi; and serving as a scientific advisor for Pfizer, AstraZeneca, and Eisai.
Jennifer L. Burns, Manager, Guidelines Support, NCCN, has disclosed no relevant financial relationships.
Click here to view all of the conﬂicts of interest for the panel.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-21-008-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 10, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing